Commentary
Phenotype: the result of a complex and still largely unknown interplay between molecules
Abstract
Cholangiocarcinoma (CCA) is a highly malignant tumor and the second-most common primary liver cancer. Chronic inflammation and cholestasis predispose to CCA. Previous work showed a role of c-MYC upregulation in cholestatic liver injury (1), and during CCA progression using a murine model of cholestasis-associated CCA (2).
